C&EN: "The unfulfilled dream of drug reshoring"

In this week's C&EN, a very worthwhile article by Aayushi Pratap:

...In response, the federal government began funding start-ups and groups like the API Innovation Center in an effort to increase domestic production of small-molecule APIs and finished medicines. But industry watchers say the private sector generally isn’t following the government’s lead. While drug companies and contract manufacturers are putting huge sums into US plants for newer treatment modalities such as biologics, peptides, and antibody-drug conjugates (ADCs), traditional small-molecule APIs are getting little investment.

Hui-Yin “Harry” Li, president of Wilmington PharmaTech, a Delaware-based API maker, says some biotechnology and large pharmaceutical firms are attempting to move the drug ingredients they need back to the US, though not many have been successful. “This is largely due to the limited domestic manufacturing capacity,” he says. His company, which already had three facilities in Newark, Delaware, added a pilot plant in 2020 to manufacture highly potent APIs and ADCs. But building such plants in the US remains costly and time consuming, according to Li...

Lots of good quotes within. Read the whole thing!